Anti-proliferative lichen compounds with inhibitory activity on 12(S)-HETE production in human platelets

被引:76
作者
Bucar, F
Schneider, I
Ögmundsdóttir, H
Ingólfsdóttir, K
机构
[1] Univ Iceland, Fac Pharm, IS-107 Reykjavik, Iceland
[2] Graz Univ, Inst Pharmacognosy, A-8010 Graz, Austria
[3] Iceland Canc Soc, Mol & Cell Biol Res Lab, Reykjavik, Iceland
关键词
12-lipoxygenase; 12(S)-HETE; lichen; protolichesterinic acid; lobaric acid; baeomycesic acid; usnic acid; parietin;
D O I
10.1016/j.phymed.2004.03.004
中图分类号
Q94 [植物学];
学科分类号
071001 ;
摘要
Several lichen compounds, i.e. lobaric acid (1), a P-orcinol depsidone from Stereocaulon alpinum L., (+)-protolichesterinic acid (2), an aliphatic alpha-methylene-gamma-lactone from Cetraria islandica Laur. (Parmeliaccae), (+)-usnic acid (3), a dibenzofuran from Cladonia arbuscula (Wallr.) Rabenh. (Cladoniaceae), parietin (4), an anthraquinone from Xanthoria elegans (Link) Th. Fr. (Calaplacaceae) and baeomycesic acid (5), a beta-orcinol depside isolated from Thamnolia vermicularis (Sw.) Schaer. var. subuliformis (Ehrh.) Schaer. were tested for inhibitory activity on platelet-type 12(S)-lipoxygenase using a cell-based in vitro system in human platelets. Lobaric acid (1) and (+)protolichesterinic acid (2) proved to be pronounced inhibitors of platelet-type 12(S)-lipoxygenase, whereas baeomycesic acid (5) showed only weak activity (inhibitory activity at a concentration of 100 mug/ml: 1 93.4 +/- 6.62%, 2 98,5 +/- 1.19%, 5 14.7 +/- 2.76%). Usnic acid (3) and parietin (4) were not active at this concentration. 1 and 2 showed a clear dose-response relationship in the range of 3.33-100 mug/ml. According to the calculated IC50 values the highest inhibitory activity was observed for the depsidone 1 (IC50 = 28.5 muM) followed by 2 (IC50 = 77.0 muM). The activity of 1 was comparable to that of the flavone baicalein, which is known as a selective 12(S)-lipoxygenase inhibitor (IC50 24.6 muM). (C) 2004 Elsevier GmbH. All rights reserved.
引用
收藏
页码:602 / 606
页数:5
相关论文
共 20 条
[1]   Lipoxygenase and cyclooxygenase metabolism: New insights in treatment and chemoprevention of pancreatic cancer [J].
Xian-Zhong Ding ;
Rene Hennig ;
Thomas E Adrian .
Molecular Cancer, 2 (1)
[2]   Antimycobacterial activity of lichen metabolites in vitro [J].
Ingolfsdottir, K ;
Chung, GAC ;
Skulason, VG ;
Gissurarson, SR ;
Vilhelmsdottir, M .
EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES, 1998, 6 (02) :141-144
[3]   Inhibitory effects of baeomycesic acid from the lichen Thamnolia subuliformis on 5-lipoxygenase in vitro [J].
Ingolfsdottir, K ;
Wiedemann, B ;
Birgisdottir, M ;
Nenninger, A ;
Jonsdottir, S ;
Wagner, H .
PHYTOMEDICINE, 1997, 4 (02) :125-128
[4]  
Ingolfsdottir K, 1994, Phytomedicine, V1, P187, DOI 10.1016/S0944-7113(11)80063-2
[5]   Inhibitory effects of the lichen metabolite lobaric acid on arachidonate metabolism in vitro [J].
Ingolfsdottir, K ;
Gissurarson, SR ;
MullerJakic, B ;
Breu, W ;
Wagner, H .
PHYTOMEDICINE, 1996, 2 (03) :243-246
[6]   Solubilization of the lichen metabolite (+)-usnic acid for testing in tissue culture [J].
Kristmundsdóttir, T ;
Aradóttir, HA ;
Ingólfsdóttir, K ;
Ögmundsdóttir, HM .
JOURNAL OF PHARMACY AND PHARMACOLOGY, 2002, 54 (11) :1447-1452
[7]  
NATARAJAN R, 1998, FRONT BIOSCI, V3, P81
[8]   Cyclooxygenase, lipoxygenase and tumor angiogenesis [J].
Nie, D ;
Honn, KV .
CELLULAR AND MOLECULAR LIFE SCIENCES, 2002, 59 (05) :799-807
[9]   Role of eicosanoids in prostate cancer progression [J].
Nie, DT ;
Che, M ;
Grignon, D ;
Tang, KQ ;
Honn, KV .
CANCER AND METASTASIS REVIEWS, 2001, 20 (3-4) :195-206
[10]  
Ogmundsdottir HM, 1998, J PHARM PHARMACOL, V50, P107, DOI 10.1111/j.2042-7158.1998.tb03312.x